by Stacey Johnson | Aug 30, 2024
This has never happened before. In eight years of hosting the blog carnival, we have never encountered a situation where the conclusions have been so similar. Given this year’s topic, the optimism is a good thing. So here is our topic: Venture financing in cell...
by Kevin Robb | Aug 22, 2024
Last month, the U.S. Food and Drug Administration (FDA) agreed to formally review a revised Biologics License Application (BLA) from Mesoblast for their mesenchymal stromal cell (MSC) product, remestemcel-L. The submission represents the third attempt by the company...
by Laya Kiani | Aug 15, 2024
According to the World Health Organization (WHO), in 2017, total global spending on health reached US$7.8 trillion and, by 2020, this figure had leapt to $9 trillion as governments raced to contain the first wave of COVID-19. The WHO estimates that worldwide spending...
by Laya Kiani | Jul 11, 2024
Intellectual property (IP) rights in regenerative medicine (RM) are crucial for sparking innovation and staying ahead in a competitive market. Protecting inventions through patents and other IP rights encourages investment by giving inventors exclusive market rights....
Comments